The IGBA maintains dialogue with other national, regional, and international bodies to ensure patient access to high-quality, safe, and effective medicines while reducing costs in pharmaceutical care.
The International Generic and Biosimilar Medicines Association (IGBA) has formed a CEO Advisory Committee with 13 leaders from companies based in Europe, the United States, Canada, India, Israel, and Japan.
The IGBA, which dates to 1997 when it was founded as the International Generic Pharmaceutical Alliance, is incorporated in Geneva, Switzerland, and is an accredited member of the World Health Organization. According to the group’s website, the IGBA maintains dialogue with other national, regional, and international bodies to ensure patient access to high quality, safe, and effective medicines while reducing costs in pharmaceutical care.
Vivian Frittelli, IGBA chair, said forming the CEO Advisory Committee will be a “transformative” step for the group. “This is the first time that the generic and biosimilar medicines industry’s company leadership has united in a structured framework, enabling a collective voice in the global pharmaceutical space,” he added.
Members of the CEO Advisory Committee include:
"I am happy to join the CEO Advisory Committee set up by the IGBA,” said Shanghvi, of Sun Pharmaceuticals. “The generic and biosimilar industry leaders of 13 leading multinational companies coming together for the first time to discuss critical global healthcare policy issues is a great step."
Added Peix, of Towa Pharma, "This advisory committee represents a milestone for the 13 worldwide leading companies of generic, value added and biosimilar medicines. For the first time, we are officially together on facing the main actual challenges and we are all working by our common purpose: the patients."
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.